Keywords
immunoglobulin M
factor X
How to Cite
Abstract
The diagnosis of immunoglobulin M (IgM) paraproteinemia and AL amyloidosis is rare, representing 5 to 7% of the cases. IgM monoclonal gammopathy of undetermined significance (MGUS) differs from other MGUS forms due to the distinctive properties of IgM molecules, which exhibit high intrinsic viscosity and precipitate more readily than other immunoglobulin types, leading to unique clinical cases.
References
Gertz MA, Merlini G, Treon SP. Amyloidosis and Waldenström macroglobulinemia. Hematology. American Society of Hematology Education Program. 2001;257-282. https://doi.org/10.1182/asheducation-2004.1.257.
Tedeschi A, Conticello C, Rizzi R, Benevolo G, Laurenti L, Petrucci MT, Zaja F, Varettoni, M. Diagnostic framing of IgM monoclonal gammopathy: Focus on Waldenström macroglobulinemia. Hematological Oncology. 2019;37(2),117-128. https://doi.org/10.1002/hon.2539.
Girard LP, Soekojo CY, Ooi M, Chng WJ, de Mel S. Immunoglobulin M Monoclonal Gammopathies of Clinical Significance. Frontiers in Oncology. 2022; 12, 905484. https://doi.org/10.3389/fonc.2022.905484.
Rajkumar SV, Dispenzieri A, Kyle RA. Monoclonal gammopathy of undetermined significance, Waldenström macroglobulinemia, AL amyloidosis and related plasma cell disorders: diagnosis and treatment. Mayo Clinic Proceedings. 2006;81(5),693-703. https://doi.org/10.4065/81.5.693.
Lu R, Richards T. A Focus on Waldenström Macroglobulinemia and AL Amyloidosis. Journal of the dvanced Practitioner in Oncology. 2022;13(Suppl 4),45-56. https://doi.org/10.6004/jadpro.2022.13.5.14.
Dejhansathit S, Suvannasankha A. Acquired FactorX Deficiency in Patients with Primary Light Chain Amyloidosis. J Investig Med High Impact Case Rep. 2019 Jan-Dec;7:2324709619832332. doi:10.1177/2324709619832332.
Zeitler KD, Blatt PM. Amyloidosis and factor X deficiency. Southern Medical Journal. 1982;75(3),306-312. https://doi.org/10.1097/00007611-198203000-00016.
All material published in the journal HEMATOLOGÍA (electronic and print version) is transferred to the Argentinean Society of Hematology. In accordance with the copyright Act (Act 11 723), a copyright transfer form will be sent to the authors of approved works, which has to be signed by all the authors before its publication. Authors should keep a copy of the original since the journal is not responsible for damages or losses of the material that was submitted. Authors should send an electronic version to the email: revista@sah.org.ar